Speakers

Expand/Collapse

Jason Fontenot
Chief Scientific Officer
Immusoft

Day One

Thursday 13th December 2018

11:45 am | Panel Discussion: Choosing the Best Indications to Maximize Benefit to Patients

Joseph Leventhal
Professor of Surgery
Northwestern Feinberg School of Medicine

Day One

Thursday 13th December 2018

9:15 am | Regulatory T Cell Therapy for Organ Transplantation and Autoimmune Diseases: The Northwestern Experience

John Koreth
Director of Translational Research, Stem Cell Transplantation
Dana Farber Cancer Institute

Day Two

Thursday 13th December 2018

3:15 pm | Session Details to be Confirmed

David Hafler
Professor of Immunobiology
Yale School of Medicine

Martí Dalmases Arnella
Chief Executive Officer
Ahead Therapeutics

Day Two

Thursday 13th December 2018

12:45 pm | Antigen Specific Immune Tolerance Generation Mimicking Apoptotic Cells: PS-Liposomes Encapsulating Auto-Ag

David Schubert
Principal Scientist
Roche

Day One

Thursday 13th December 2018

2:15 pm | A Novel IgG-IL2 Mutein to Selectively Activate T Regulatory Cells

Piotr Trzonkowski
Scientific Advisor, PolTREG; Professor
Medical University of Gdansk

Day One

Thursday 13th December 2018

9:45 am | ATMP-Grade T Regulatory Cells as a Drug for Autoimmune Diseases

Andrew Scharenberg
Chief Scientific Officer
Casebia Therapeutics

Andrew M. Scharenberg, MD, is an Attending Physician at Seattle Children’s Hospital, a Professor in the Department of Pediatrics, and an Adjunct Professor in the Department of Immunology at the University of Washington School of Medicine in Seattle.  He presently serves as Chief Scientific Officer of Casebia Therapeutics in Cambridge, MA. Prior to joining Casebia, Dr. Scharenberg co-directed (with David Rawlings M.D.) the Program in Cell and Gene Therapy at Seattle Children’s Research Institute, working to translate cell and gene therapies for the treatment of inherited immunologic and blood diseases. This work led to the development of a program in engineered regulatory T-cells, recently partnered with Casebia for the purpose of developing gene edited cell therapeutics

Peter Weber
Director, Autoimmune Research
Immunocore

Elmar Jaeckel
Gastroenterology, Hepatology & Endocrinology, Research Group Immune Tolerance
Hannover Medical School

Day Two

Thursday 13th December 2018

9:45 am | CAR nTregs for Tolerance Induction in Transplantation and Autoimmunity

Marc Martinez- Llordella
Senior Lecturer
King’s College London

Day One

Thursday 13th December 2018

12:15 pm | Use of Low-Dose IL-2 Therapy to Modulate the Treg Homeostasis & Combinational Therapies to Enhance Treg Function in Transplantation

Kevin Otipody
Director of Immunology
Pandion Therapeutics

Day One

Thursday 13th December 2018

2:45 pm | Localized Immunomodulation of Regulatory T cells in the Gut

Anthony Conway
Scientist III
Sangamo Therapeutics

Day Two

Thursday 13th December 2018

9:15 am | Engineering CAR Regulatory T Cells (CAR-Tregs) for Autoimmunity, Inflammation & Transplantation

Everett Meyer
Assistant Professor of Medicine
Stanford University Medical Center

Day One

Thursday 13th December 2018

11:45 am | Panel Discussion: Choosing the Best Indications to Maximize Benefit to Patients

10:15 am | Clinical Trials and Pre-Clinical Studies of T Regulatory Therapy for Graft-versus-Host Disease and Transplantation Tolerance

Nora Lieske
R&D Manager, Cell Therapy
ThermoFisher Scientific

Day Two

Thursday 13th December 2018

10:15 am | From Process Development to Workflow: What to Consider for Successful Scaling

Rupert Sandbrink
Chief Medical Officer
Topas Therapeutics

Day Two

Thursday 13th December 2018

2:15 pm | Leveraging Tolerogenic Nanoparticles to Induce Antigen-Specific Immune Tolerance in vivo

Robert Levy
Scientific Advisor, Pelican Therapeutics; Professor
University of Miami Miller School of Medicine

Day One

Thursday 13th December 2018

11:45 am | Panel Discussion: Choosing the Best Indications to Maximize Benefit to Patients

Day Two

Thursday 13th December 2018

2:45 pm | Reagents that Target TNFRSF25 in vivo Effectively to Modulate the CD4+FoxP3+ Treg Compartment